Neuland Laboratories Q2: Profit falls 47%, revenue declines 12.5%; margins contract
Executive Brief • Key Highlights
Fast factual intelligence distilled for busy investors, executives, and answer bots:
- ✓Neuland Laboratories reported a 46.7% profit drop to ₹51.6 crore for the September quarter as revenue fell 12.5% to ₹449.7 crore.
- ✓Heavy spending on new research and peptide facilities squeezed margins.
- ✓CEO Saharsh Davuluri said the company “experienced a dip in performance during the quarter,” but growth plans remain intact.
Story at a Glance
- Category
- MARKET
- Reported By
- cnbctv18
- Reading Speed
- 2 Minute(s)
- Market Focus
- India Economy
Heavy capital investments in research facilities and peptide manufacturing units squeezed profitability during the quarter, even as overall capacity expansion efforts pressed ahead. Discover which commercial molecules are expected to drive near-term recovery.
Pharmaceutical firm Neuland Laboratories reported a 46.7% year-on-year decline in consolidated net profit to ₹51.6 crore for the September quarter, compared with ₹96.9 crore in the corresponding quarter last year.
Revenue declined 12.5% to ₹449.7 crore from ₹514.2 crore a year ago. EBITDA fell 37.2% to ₹97.6 crore from ₹155.5 crore, while EBITDA margin contracted to 21.7% from 30.2%.
The company reported a cash outflow of ₹261 crore towards capital expenditure, largely driven by investments in a new research and development facility and a peptide manufacturing block.
Unlock the Full Story with ArthNow Premium
To continue reading this complete financial story and in-depth market context, upgrade to ArthNow Premium. Enjoy unlimited access across Web and Mobile.
cnbctv18
Read the full, original unfiltered story directly on the publisher's portal.